Medical Doctor Program year 2025 Reported 2023–2025 Source: CMS Open Payments, 2026 publication

Daniel Smigielski

Sports Medicine Birmingham, AL Medical Doctor

NPI 1881184133 CMS profile 11469621

805 Saint Vincents Dr Ste 100, Birmingham, AL 35205

Open in the dashboard

General payments

$31,186

60 records reported · program years 2023–2025

Research payments

$0

Paid to them · None reported · program years 2023–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Daniel Smigielski of Birmingham, AL is reported in the CMS Open Payments database as having received $31,186 across 60 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 77th percentile of Sports Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $886 17
2024 General $6,199 30
2023 General $24,101 13

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Daniel Smigielski
  • Sports Medicine median
  • Middle half of Sports Medicine
  • National median

In program year 2025, general payments to Daniel Smigielski were reported at $886. Among 2,404 Sports Medicine profiles paid that year, the median was $664 and the middle half received between $172 and $3,055.

Show as a table
Year Daniel Smigielski Sports Medicine median Middle half National median
2019 $0 $1,176 $199–$4,249 $163
2020 $0 $708 $96–$2,890 $114
2021 $0 $1,213 $152–$3,994 $132
2022 $0 $1,230 $159–$3,998 $149
2023 $24,101 $584 $146–$2,836 $160
2024 $6,199 $628 $163–$3,168 $164
2025 $886 $664 $172–$3,055 $169

Breakdown

Who paid General payments · program years 2023–2025
  1. Arthrex, Inc. $20,166 2 payments
  2. Smith+Nephew, Inc. $6,709 10 payments
  3. Zimmer Biomet Holdings, Inc. $2,308 21 payments
  4. Prime Surgical, LLC $488 1 payment
  5. Stryker Corporation $432 4 payments
  6. DePuy Synthes Sales Inc. $306 3 payments
  7. Gentleman Orthopedic Solutions $185 3 payments
  8. Bioventus LLC $178 3 payments
  9. Vertex Pharmaceuticals Incorporated $97 4 payments
  10. Vericel Corporation $87 3 payments
  11. Other $230 6 payments

Every payment, record by record

What the payments were for General payments · program years 2023–2025
  1. Grant $22,917 2 payments
  2. Food and Beverage $3,551 46 payments
  3. Education $2,917 1 payment
  4. Travel and Lodging $1,802 11 payments
Products named General payments · program years 2023–2025
  1. Comprehensive Shoulder System $1,273 12 payments
  2. Avenir $941 7 payments
  3. Bioinductive Implant with Arthroscopic Delivery System - Medium $402 3 payments
  4. REAL INTELLIGENCE $345 4 payments
  5. HEALIX KNOTLESS PEEK $194 1 payment
  6. DYNATAPE $194 1 payment
  7. OMEGA $173 1 payment
  8. JOURNEY II $167 2 payments
  9. LEGION Revision $167 2 payments
  10. JOURNEY II XR $167 2 payments
  11. Other $1,587 29 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

28

Median for Orthopedic Surgery: 203

Drug cost

$126

Median for Orthopedic Surgery: $1,433

Branded share of claims

0%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Methylprednisolone Generic 17 $93
Meloxicam Generic 11 $33

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 76 billing codes

Paid by Medicare

$39,865

Of which drugs: $1,070

Medicare patients

122

Average age 74

Services billed

2,373

72 women, 50 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 66%
Diabetes 35%
Ischemic heart disease 30%
Depression 30%
Chronic kidney disease 25%
Cancer 23%
Atrial fibrillation 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 24 1,960 $194

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

60 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Sports Medicine in Alabama

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record